On May 12, 2026, a paper published in The Lancet did something that 170 million women worldwide had been waiting over a decade for: it officially retired the name “polycystic ovary syndrome.”
The new name is polyendocrine metabolic ovarian syndrome, or PMOS. And it represents far more than a rebrand. It is the product of 14 years of global collaboration, more than 22,000 survey responses from patients and clinicians across every world region, and the backing of 56 leading academic, clinical, and patient organizations including the Endocrine Society, the American College of Obstetricians and Gynecologists, and the International Federation of Gynecology and Obstetrics.
This was not a committee quietly swapping letters. It was the largest consensus process in reproductive endocrinology history.
What Actually Changed
The old name, PCOS, described the condition as being about cysts on the ovaries. The problem? Many women with the condition do not have ovarian cysts. And those who do have cysts do not necessarily have the syndrome. The name was inaccurate from the start, coined in 1935 based on autopsy findings and never meaningfully updated.
For nearly a century, the misleading name caused real harm. Women were told their ultrasounds looked normal and therefore they did not have PCOS, when in fact the metabolic and hormonal disruptions were the core of the disease. The ovarian appearance was, at most, one piece of a much larger puzzle.
PCOS was never primarily about your ovaries. It is a multisystem endocrine and metabolic condition that also affects your ovaries. The new name finally reflects that reality.
Why the Name Matters More Than You Think
Names shape how conditions are researched, funded, diagnosed, and treated. When PCOS was framed as a gynecological problem, it was primarily managed by gynecologists. The metabolic workup evaluating insulin resistance, lipids, and glucose tolerance was often deprioritized or skipped entirely.
The consequences were significant. An estimated 70 percent of women with the condition remain undiagnosed. Average time to diagnosis is over two years, and many women report visiting three or more doctors before getting an answer. Women with lean body types were routinely missed because they did not fit the stereotype of a patient who was overweight with visible acne and excess hair growth.
By renaming the condition to emphasize its endocrine and metabolic nature, the global consensus aims to shift clinical thinking. PMOS patients should be screened for insulin resistance, cardiovascular risk factors, and metabolic syndrome as standard care, not as afterthoughts.
Breaking Down the New Name
Each word in polyendocrine metabolic ovarian syndrome was chosen deliberately through the consensus process.
Polyendocrine
This recognizes that the condition involves multiple interacting hormonal disturbances. Insulin, androgens, luteinizing hormone, follicle-stimulating hormone, and neuroendocrine hormones are all involved. It is not an isolated ovarian disorder. The entire hormonal axis is disrupted.
Metabolic
This acknowledges what researchers have known for decades: PMOS carries inherent metabolic features including insulin resistance, increased risk for type 2 diabetes, and elevated cardiovascular risk. A 2024 meta-analysis published in the Journal of the American Heart Association confirmed that women with the condition face significantly elevated risk for cardiovascular events, independent of weight.
Ovarian
The ovarian connection is retained because ovulatory disturbances and infertility remain defining features of the syndrome for many women. But by placing “ovarian” after “polyendocrine” and “metabolic,” the name signals that the ovary is downstream of the broader hormonal and metabolic disruption, not the primary driver.
How This Affects Your Diagnosis
Diagnostic criteria are not changing overnight. The Rotterdam criteria, which require two of three features (oligo-anovulation, clinical or biochemical hyperandrogenism, and polycystic ovarian morphology on ultrasound), remain in use. But the expectation is that the name change will progressively shift clinical practice in several important ways.
First, metabolic screening should become routine. Every PMOS patient should have fasting glucose, insulin, HbA1c, and a lipid panel checked at diagnosis and monitored regularly. Second, lean women with irregular periods will be less likely to be dismissed because the new name does not center body weight. Third, referral patterns should broaden. PMOS patients benefit from multidisciplinary care including endocrinology, cardiology, dermatology, and mental health, not just gynecology.
ICD coding updates and medical education curriculum changes are already being developed. The Endocrine Society and other organizations are working on 8-stage implementation strategies to ensure the terminology shift is adopted consistently worldwide.
The Peptide Connection to PMOS
The rename matters especially for the peptide therapy landscape because it reframes PMOS as a metabolic-first condition, and metabolic dysfunction is exactly where peptide therapies have the strongest evidence base.
Three categories of peptides are particularly relevant to the newly understood PMOS framework:
GLP-1 Receptor Agonists (Targeting Insulin Resistance)
Semaglutide and tirzepatide address the metabolic root of PMOS. A meta-analysis of 8 randomized trials found that GLP-1 receptor agonists were superior to metformin in improving insulin sensitivity and reducing BMI in women with the condition. By reducing insulin resistance, they normalize the hormonal cascade that drives androgen excess and anovulation. Studies show reductions in total testosterone and free androgen index, improvements in menstrual regularity, and reduced hirsutism scores over 24 weeks.
Kisspeptin (Targeting Ovulatory Dysfunction)
Kisspeptin-10 is a master regulator of the reproductive axis. Research from Imperial College London demonstrated that kisspeptin administration can stimulate reproductive hormone secretion and rescue ovulation in women with PCOS. A 2026 study published in Frontiers in Endocrinology found that kisspeptin is involved in the pathological processes of ovarian dysfunction in PMOS and may have predictive value for pregnancy outcomes.
BPC-157 (Targeting Inflammation)
Chronic low-grade inflammation is one of the four root dysfunctions of PMOS. BPC-157 has demonstrated anti-inflammatory properties in preclinical models and is being studied for gut-related inflammation, which is increasingly linked to metabolic dysfunction in PMOS.
Want the deep science on each of these peptides? PeptideOnline.co has the most comprehensive mechanism-of-action guides available.
Explore Peptide Profiles →What You Should Do Now
If you have been diagnosed with PCOS, your diagnosis has not changed and your treatment plan does not need to be altered immediately. What has changed is the framework your healthcare team should be using to understand and manage your condition going forward.
Consider requesting a comprehensive metabolic panel if you have not had one recently. Ask your provider about insulin resistance screening specifically. If you are being managed solely by a gynecologist, consider requesting referrals to endocrinology and, if relevant, cardiology for cardiovascular risk assessment.
If you have been told in the past that you do not have PCOS because your ultrasound was normal, the new name and its metabolic emphasis may be reason to revisit that conversation with a provider who is current on the updated terminology and diagnostic approach.
The rename is not cosmetic. It is a clinical mandate to treat the whole syndrome, not just the ovaries.